Skip to main content
Decorative image of the AMR Learning Lounge

Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay

SUMMARY

In conjunction with University of Texas Health (UTH), a multidisciplinary team, including several bioMérieux scientists, reviewed data about the impact of the BioFire® FilmArray® Meningitis/Encephalitis (ME) Panel for PCR testing on hospital length of stay (LOS) and days of antibiotic therapy. Findings from the systematic review of available research suggest that the multiplex ME panel is associated with a significant reduction in LOS and a potential reduction of the number of days of antibiotic therapy, supporting UTH antimicrobial stewardship efforts. 

FEATURED EXPERTS

Tristan Timbrook, PharmD, Director of Health Economics Outcomes Research at bioMérieux

Kyle D. Hueth, Sr. Manager, Global Medical Affairs Scientist at bioMérieux


GET STARTED

Read the study at MDPI.

Read time: 20 minutes


We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.


Global Solutions

BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel

The BIOFIRE ME Panel provides answers on 14 of the most common bacterial, viral, and yeast pathogens that cause central nervous system infections to help healthcare providers rapidly distinguish between bacterial and viral meningitis and optimize life-saving therapy. 

U.S. bioMérieux Solutions

US Solutions

BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel

The BIOFIRE ME Panel provides answers on 14 of the most common bacterial, viral, and yeast pathogens that cause central nervous system infections to help healthcare providers rapidly distinguish between bacterial and viral meningitis and optimize life-saving therapy. 

PUBLISHED BY

MDPI | Special Issue Combating Antibiotic Resistance with Precision Medicine: The Value of Diagnostics
July 22, 2022


SHARE THIS ARTICLE: